AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review
Portfolio Pulse from Vandana Singh
AstraZeneca's Calquence receives FDA Priority Review for expanded use in treating mantle cell lymphoma, with a decision expected in Q1 2025. The ECHO Phase III trial shows promising results, reducing disease progression risk by 27% and extending progression-free survival.
October 03, 2024 | 6:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's Calquence has been granted FDA Priority Review for treating mantle cell lymphoma, with promising trial results showing reduced disease progression risk. A decision is expected in Q1 2025.
The FDA's Priority Review for Calquence indicates a potentially significant expansion in its market use, which could positively impact AstraZeneca's revenues. The promising trial results further support the drug's efficacy, likely boosting investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100